The drug changing the game for patients with stubbornly high triglycerides despite statin therapy is icosapent ethyl, sold as Vascepa in the United States. It is the only triglyceride-lowering medication with proven cardiovascular outcomes benefit when added to statins, a distinction that no fibrate, no niacin supplement, and no other omega-3 product can claim. In the landmark REDUCE-IT trial, icosapent ethyl reduced major cardiovascular events by 25 percent in high-risk patients whose triglycerides remained elevated at 150 mg/dL or above even with statin-controlled LDL cholesterol. Since its launch in January 2020, it has been prescribed more than 25 million times. But icosapent ethyl is no longer the only option worth knowing about.
In 2025, the FDA approved olezarsen, marketed as Tryngolza, as the first-ever treatment for familial chylomicronemia syndrome, a rare and dangerous genetic condition that sends triglycerides soaring into the thousands. Meanwhile, RNA interference therapies like plozasiran are delivering triglyceride reductions of 80 percent in clinical trials. At the same time, the FDA slapped new warning labels on fibrates, the old standby add-on, stating plainly that they do not reduce cardiovascular risk. Cardiovascular researchers have started calling 2025 “the year of triglyceride-lowering therapies,” and for people concerned about brain health and dementia risk, these developments matter more than most headlines suggest. This article covers why triglycerides matter for your brain, how the leading drugs work, what the newest approvals mean for patients with severe cases, why fibrates lost their credibility, and what experimental treatments are coming next.
Table of Contents
- What Is the Drug That Lowers Triglycerides When Statins Alone Fall Short?
- How Olezarsen Targets the Root Cause of Severe Triglyceride Disorders
- Why the FDA Stripped Fibrates of Their Cardiovascular Claims
- How RNA Interference Therapies Compare to Current Options
- What the Triglyceride-Brain Health Connection Means for Dementia Risk
- Investigational Drugs That Could Reshape Treatment in the Next Few Years
- Where Triglyceride Treatment Is Heading After 2025
- Conclusion
- Frequently Asked Questions
What Is the Drug That Lowers Triglycerides When Statins Alone Fall Short?
Statins are the backbone of cholesterol management, but they were designed primarily to lower LDL cholesterol, not triglycerides. Most statins reduce triglycerides by only 10 to 20 percent, which leaves millions of patients with residual cardiovascular risk even after hitting their LDL targets. This is where icosapent ethyl steps in. Unlike over-the-counter fish oil supplements, which contain a mixture of EPA and DHA and have failed to show cardiovascular benefit in major trials, icosapent ethyl is a highly purified form of eicosapentaenoic acid, or EPA, delivered at a prescription dose of 4 grams daily. The FDA approved icosapent ethyl in December 2019 as the first triglyceride-lowering agent proven to reduce cardiovascular events on top of statin therapy.
Its indication is specific: patients with established atherosclerotic cardiovascular disease or multiple risk factors, LDL cholesterol below 70 mg/dL on a maximally tolerated statin, and fasting triglycerides between 150 and 500 mg/dL. At the European Society of Cardiology congress in 2025, new analyses from the REDUCE-IT data showed that Vascepa therapy resulted in 9 percent fewer total hospitalizations and reduced cardiovascular risk in certain high-risk subgroups, reinforcing its place in treatment guidelines. For dementia care specifically, this matters because elevated triglycerides have been linked in observational research to increased risk of vascular cognitive impairment. The same atherosclerotic processes that cause heart attacks also compromise blood flow to the brain. A drug that reduces cardiovascular events by a quarter may well be protecting cerebral vasculature at the same time, though dedicated cognitive outcome trials have not yet been completed for icosapent ethyl.
How Olezarsen Targets the Root Cause of Severe Triglyceride Disorders
For patients whose triglycerides are not merely elevated but dangerously high, often above 1,000 mg/dL, icosapent ethyl is not enough. These patients, particularly those with familial chylomicronemia syndrome, face repeated bouts of acute pancreatitis that can be life-threatening. Until 2025, there was no FDA-approved treatment specifically for FCS. Patients were told to follow extremely restrictive diets limiting fat to as little as 10 to 15 grams per day, a regimen that is miserable to maintain and often insufficient. Olezarsen, now marketed as Tryngolza, was approved by the FDA in 2025 as the first-ever treatment for adults with FCS. It works by a fundamentally different mechanism than icosapent ethyl.
Rather than supplementing EPA, olezarsen is an antisense oligonucleotide that reduces the body’s production of apolipoprotein C-III, a liver protein that regulates triglyceride metabolism. By suppressing apoC-III, olezarsen demonstrated a placebo-adjusted triglyceride reduction of up to 72 percent and an 85 percent reduction in acute pancreatitis events. Nearly 90 percent of patients treated with olezarsen achieved triglyceride levels below 500 mg/dL, the threshold above which pancreatitis risk climbs steeply. However, olezarsen’s current approval is limited to FCS, which affects roughly one in every 100,000 to one million people depending on the population studied. If your triglycerides are moderately elevated but you do not have this rare genetic condition, olezarsen is not currently an option. That said, on February 26, 2026, the FDA accepted a supplemental new drug application for priority review to expand olezarsen’s use to severe hypertriglyceridemia more broadly, with a target action date of June 30, 2026. If approved for that wider indication, it could become available to a much larger patient population.
Why the FDA Stripped Fibrates of Their Cardiovascular Claims
For decades, fibrates like fenofibrate and gemfibrozil were the default add-on when statins failed to bring triglycerides under control. Doctors prescribed them with the reasonable assumption that lowering triglycerides would translate into fewer heart attacks and strokes. That assumption turned out to be wrong, at least for fibrates. The clearest evidence came from the PROMINENT trial, published in the New England Journal of Medicine in November 2022. this study enrolled 10,497 statin-treated patients with type 2 diabetes and tested pemafibrate, a newer selective fibrate designed to be more potent and better tolerated than older options. Despite successfully lowering triglycerides, pemafibrate showed no cardiovascular benefit whatsoever.
The primary outcome occurred in 3.6 percent of pemafibrate patients compared with 3.5 percent of those on placebo, a difference that was statistically meaningless with a P value of 0.67. Lowering the number on the lab report did not translate into fewer events. On October 14, 2025, the FDA formally changed fenofibrate labels to highlight that fibrates are not associated with cardiovascular benefits. This label change was prompted by a Citizen Petition filed by HealthyWomen, a patient advocacy organization. While fibrates can still lower triglycerides by up to 50 percent, which may be useful for reducing pancreatitis risk in patients with very high levels, the notion that they protect against heart attacks and strokes is now officially discredited. For anyone managing cardiovascular or brain health, this distinction between lowering a lab value and reducing actual clinical events is critical.
How RNA Interference Therapies Compare to Current Options
The next wave of triglyceride-lowering drugs goes beyond traditional pharmacology into the realm of genetic medicine. Plozasiran, developed by Arrowhead Pharmaceuticals and marketed under the brand name Redemplo, is an RNA interference therapeutic that, like olezarsen, targets apoC-III production. But instead of using an antisense oligonucleotide approach, it uses small interfering RNA to silence the gene responsible for apoC-III at the messenger RNA level. In the Phase 3 PALISADE study, plozasiran at the 25 mg dose achieved an 80 percent median reduction in fasting triglycerides after 10 months, compared with only 17 percent for placebo. That is a striking result, and it edges out olezarsen’s 72 percent reduction, though head-to-head comparisons between the two drugs have not been conducted. Arrowhead has signaled its confidence in plozasiran by putting zodasiran, a competing molecule in their own pipeline, on hold to focus resources on marketing and expanding plozasiran’s reach.
The tradeoff with these genetic-level therapies is complexity. Both olezarsen and plozasiran require subcutaneous injections rather than daily pills. They are new enough that long-term safety data spanning decades is not yet available. And their initial target populations are patients with rare, severe genetic conditions, not the average person with triglycerides of 200 mg/dL who also takes a statin. For the majority of patients with moderate triglyceride elevation and cardiovascular risk, icosapent ethyl remains the most proven and accessible option. But for those with severe or genetically driven hypertriglyceridemia, the new therapies represent a genuine shift from managing symptoms to addressing root causes.
What the Triglyceride-Brain Health Connection Means for Dementia Risk
The conversation about triglycerides has historically been framed entirely around heart disease and pancreatitis, but the implications for brain health are becoming harder to ignore. The brain depends on robust blood flow through small vessels that are particularly vulnerable to the atherosclerotic and inflammatory processes associated with metabolic dysfunction. Elevated triglycerides are a component of metabolic syndrome, which has been associated in multiple epidemiological studies with increased risk of vascular dementia and, to a lesser extent, Alzheimer’s disease. One limitation worth stating clearly is that no triglyceride-lowering drug has been tested in a randomized controlled trial with dementia or cognitive decline as a primary endpoint. The cardiovascular benefit of icosapent ethyl is well established, and it is biologically plausible that reducing cardiovascular events would also protect cognitive function, particularly against vascular contributions to dementia.
But plausibility is not proof. Patients and caregivers should be cautious about any claim that a specific triglyceride drug prevents dementia. What can be said with confidence is that uncontrolled cardiovascular risk factors, including elevated triglycerides, are among the modifiable contributors to cognitive decline, and managing them aggressively is consistent with current brain health guidelines. There is also a practical warning here. Some patients, especially older adults managing multiple medications, may hesitate to add yet another drug. The decision to add icosapent ethyl or any triglyceride-lowering therapy should involve a frank conversation with a physician about the individual’s total cardiovascular risk, their existing medication burden, kidney function, and bleeding risk, since high-dose EPA can modestly increase the chance of atrial fibrillation and bleeding events.
Investigational Drugs That Could Reshape Treatment in the Next Few Years
Beyond the drugs already approved or in late-stage trials, several investigational therapies are generating early excitement. DR10624 reduced triglyceride levels by more than 60 percent in most patients with severe hypertriglyceridemia in a 12-week trial, according to data presented through the American Heart Association. While these are early-stage results that require confirmation in larger and longer studies, the magnitude of triglyceride reduction is in the range that clinical experience suggests could meaningfully reduce pancreatitis risk.
Pegozafermin, a long-acting analog of fibroblast growth factor 21, takes yet another approach. Rather than targeting apoC-III or supplementing EPA, it works through the FGF21 pathway, which regulates triglyceride metabolism through multiple mechanisms including enhanced fatty acid oxidation and reduced hepatic lipogenesis. It is also being studied for nonalcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis, reflecting the deep connection between liver fat, triglycerides, and metabolic disease. If pegozafermin proves effective in both conditions simultaneously, it could become a uniquely attractive option for the large population of patients who have both high triglycerides and fatty liver disease.
Where Triglyceride Treatment Is Heading After 2025
The treatment landscape for high triglycerides looks fundamentally different than it did even three years ago. The old model of prescribing a fibrate and hoping for the best has been replaced by a more nuanced approach: icosapent ethyl for patients with moderate elevation and proven cardiovascular risk, antisense and RNAi therapies for severe genetic cases, and a growing pipeline of novel agents targeting different biological pathways. If the FDA grants olezarsen’s expanded indication for severe hypertriglyceridemia by its June 2026 target date, the number of patients eligible for genetically targeted triglyceride therapy will increase substantially.
For people navigating dementia care and brain health, the takeaway is that triglyceride management is no longer a backwater of cardiovascular medicine. It has become one of the most active areas of drug development, and the drugs emerging from this work may turn out to protect not just hearts but brains. Staying informed about these options, and asking physicians specifically about residual triglyceride risk even when LDL is well controlled, is one of the more actionable steps a patient or caregiver can take.
Conclusion
The era of treating elevated triglycerides as an afterthought is over. Icosapent ethyl remains the proven standard for patients whose triglycerides stay stubbornly high despite statin therapy, backed by the REDUCE-IT trial’s 25 percent reduction in major cardiovascular events and over 25 million prescriptions since 2020. For the most severe cases, olezarsen and plozasiran represent genuine breakthroughs, offering triglyceride reductions of 72 to 80 percent through mechanisms that address the genetic roots of the problem rather than just the symptoms.
Meanwhile, the FDA’s decision to strip fibrates of their cardiovascular benefit claims has clarified what these older drugs can and cannot do. If you or someone you care for has elevated triglycerides despite statin therapy, the most important next step is a specific conversation with a physician about residual cardiovascular risk and whether icosapent ethyl or another targeted therapy is appropriate. Do not assume that a statin alone is handling the problem, and do not rely on over-the-counter fish oil as a substitute for prescription-grade treatment. As the connection between cardiovascular health and cognitive function becomes clearer, managing every modifiable risk factor, including triglycerides, is one of the most concrete things you can do to protect long-term brain health.
Frequently Asked Questions
Is prescription icosapent ethyl the same thing as fish oil supplements I can buy at the store?
No. Over-the-counter fish oil contains a mixture of EPA and DHA in varying concentrations, and major clinical trials of mixed omega-3 supplements have not shown cardiovascular benefit. Icosapent ethyl is a highly purified, FDA-approved form of EPA alone, delivered at a specific 4-gram daily dose. The distinction matters because the REDUCE-IT trial’s results apply only to icosapent ethyl, not to generic fish oil products.
Can icosapent ethyl or other triglyceride drugs prevent dementia?
No triglyceride-lowering drug has been tested in a randomized trial with dementia as a primary endpoint. However, elevated triglycerides contribute to cardiovascular disease processes that also damage brain vasculature, and reducing cardiovascular events may indirectly protect cognitive function. This is plausible but unproven, and no one should take these drugs specifically for dementia prevention without medical guidance.
Why did the FDA change the labels on fibrates like fenofibrate?
On October 14, 2025, the FDA updated fenofibrate labels to state that fibrates are not associated with cardiovascular benefits. This followed the PROMINENT trial, which showed that pemafibrate provided zero cardiovascular benefit despite lowering triglycerides in over 10,000 patients. The label change means fibrates may still be used to lower triglycerides and reduce pancreatitis risk, but not with the expectation of preventing heart attacks or strokes.
Who qualifies for olezarsen (Tryngolza)?
Currently, olezarsen is approved only for adults with familial chylomicronemia syndrome, a rare genetic condition causing extremely high triglycerides. However, the FDA accepted a supplemental application in February 2026 to expand its use to severe hypertriglyceridemia more broadly, with a decision expected by June 30, 2026. If approved, the eligible population would grow significantly.
Are there side effects to be aware of with icosapent ethyl?
The most notable risks include a modest increase in atrial fibrillation and a slightly elevated bleeding risk, particularly in patients already on blood thinners. Joint pain and peripheral edema have also been reported. These risks should be weighed against the proven cardiovascular benefit, especially in older adults who may already be on multiple medications.
What is the difference between olezarsen and plozasiran?
Both drugs target apolipoprotein C-III to reduce triglyceride production, but they use different technologies. Olezarsen is an antisense oligonucleotide, while plozasiran uses RNA interference. In clinical trials, plozasiran achieved an 80 percent triglyceride reduction compared to olezarsen’s 72 percent, though no head-to-head trial has been conducted. Both require subcutaneous injection rather than oral dosing.
